Published on

Clinical Toxicology — Reserpine

1. Overview

Reserpine is a naturally occurring indole alkaloid derived from plants of the genus Rauvolfia, particularly Rauvolfia serpentina, commonly known as Indian snakeroot.

It was historically used to treat hypertension and certain psychiatric disorders because of its ability to deplete neuronal stores of norepinephrine, dopamine, and serotonin.

Reserpine is rarely prescribed today because safer and better-tolerated antihypertensive medications are available.

The major manifestations of acute poisoning are sedation, CNS depression, bradycardia, hypotension, gastrointestinal disturbances, and occasionally hypothermia.

Severe ingestion may produce prolonged coma, respiratory depression, and circulatory collapse.

An important characteristic is that reserpine’s pharmacologic effects can persist well beyond its initial absorption and plasma distribution phases.

There is no specific antidote. Treatment is supportive, with particular attention to airway protection, hemodynamic support, and observation for delayed toxicity.

2. Forms, sources, and historical uses

Reserpine has been marketed under names including Serpasil and other proprietary formulations.

Historical preparations also combined reserpine with diuretics or additional antihypertensive medications.

Examples include formulations containing hydrochlorothiazide, chlorothiazide, or polythiazide.

Combination products require special attention because the additional ingredients may cause electrolyte abnormalities, dehydration, or other complications.

Botanical sources

Reserpine-containing alkaloids occur in several Rauvolfia species, including:

  • Rauvolfia serpentina — Indian snakeroot.
  • Rauvolfia vomitoria — African snakeroot.

Traditional preparations may contain dried root, powdered root, extracts, or teas.

The quantity of reserpine and other alkaloids varies between species and products.

Consequently, no reliable conversion can be made from a stated quantity of herbal material to an absorbed dose of reserpine.

Historical therapeutic doses

Reserpine was commonly prescribed in maintenance doses of approximately 0.1–0.25 mg daily for hypertension.

Higher doses, including 0.5 mg daily, were associated with more frequent psychiatric and other adverse effects.

These doses are included for historical identification and should not be interpreted as recommendations to begin reserpine treatment.

Contemporary clinical position

Reserpine is not a routine first-line antihypertensive medication.

Its availability and approved uses vary between countries.

Current management of hypertension generally favors medications with better-established tolerability and safety profiles.

3. Mechanism of action

Reserpine inhibits the vesicular monoamine transporter, particularly VMAT2, which normally transports monoamine neurotransmitters into intracellular storage vesicles.

The principal affected neurotransmitters include norepinephrine, dopamine, and serotonin.

Catecholamine depletion

When vesicular transport is inhibited, monoamines cannot be stored normally.

Cytoplasmic neurotransmitters are subsequently broken down by intracellular metabolic pathways.

This progressively reduces the amount available for release during neuronal stimulation.

Peripheral effects

Depletion of norepinephrine from sympathetic nerve terminals reduces sympathetic cardiovascular activity.

The resulting effects can include:

  • Reduced peripheral vascular resistance.
  • Reduced heart rate.
  • Lower blood pressure.
  • Impaired compensatory sympathetic responses.

Central effects

Depletion of monoamines in the central nervous system contributes to sedation, psychomotor slowing, and movement abnormalities.

Disturbances in central monoamine signaling may also contribute to depression.

Prolonged effects

Reserpine binds tightly to vesicular transport mechanisms, causing effects that can persist after circulating drug concentrations have declined.

Recovery depends partly on the restoration of functional transport systems and neurotransmitter stores.

This mechanism explains why clinical effects may last longer than expected from the initial plasma half-life.

4. Toxicokinetics

Reserpine is absorbed after oral ingestion and distributes extensively into body tissues.

Peak concentrations have been reported approximately one to four hours after administration, depending on formulation and study conditions.

Distribution

Reserpine enters the central nervous system and is distributed into tissues including the liver, kidneys, and adipose tissue.

Elimination

Elimination is prolonged and multiphasic.

A small pharmacokinetic study described an initial half-life of approximately 4.5 hours and a terminal half-life of approximately 11 days.

Clinical interpretation

The terminal half-life does not mean that every patient remains clinically poisoned for 11 days.

However, prolonged tissue distribution and pharmacodynamic activity may contribute to persistent or recurring effects.

Metabolism

Reserpine undergoes extensive metabolism.

Drug and metabolites are eliminated through both fecal and renal pathways.

Overdose considerations

Pharmacokinetic information after large ingestions remains limited.

The timing and duration of severe toxicity must therefore be determined clinically rather than predicted from a single half-life.

5. Toxic dose

A reliable minimum toxic or lethal dose has not been established.

Historical pediatric reports describe profound sedation or coma after ingestion of approximately 25 mg.

Recovery occurred with supportive treatment in some reported cases.

However, serious and fatal toxicity has also been documented.

Important risk factors

Severity may be influenced by:

  • Total ingested dose.
  • Patient age and body weight.
  • Concurrent antihypertensive medications.
  • Sedatives or alcohol.
  • Baseline cardiovascular disease.
  • Kidney or liver dysfunction.
  • Exposure to other Rauvolfia alkaloids.

A historical report of survival after a large dose should not be used to establish a safe ingestion threshold.

6. Clinical manifestations

Central nervous system

Sedation and lethargy are the most common neurologic findings.

Severe poisoning may produce profound somnolence, stupor, or coma.

Other reported findings include dizziness, tremor, abnormal movements, and altered responsiveness.

Respiratory system

Respiratory depression may occur with severe CNS toxicity.

Prolonged impairment of consciousness also increases the risk of aspiration.

Cardiovascular system

Bradycardia and hypotension are characteristic manifestations.

Severe cases may develop impaired perfusion or shock.

Initial hypertension

Rare historical cases describe hypertension and tachycardia, possibly associated with transient redistribution or release of catecholamines.

However, an initial hypertensive phase is not a predictable or obligatory stage of reserpine poisoning.

It should not be assumed that all patients will progress from hypertension to hypotension.

Temperature

Hypothermia may develop, particularly in severe pediatric poisoning or prolonged CNS depression.

Gastrointestinal system

Nausea, vomiting, abdominal pain, and diarrhea may occur.

Other findings

Facial flushing, nasal congestion, miosis, and other autonomic manifestations have been reported.

Pupil size is not sufficiently consistent to confirm or exclude the diagnosis.

7. Adverse effects during prolonged treatment

Depression

Reserpine has historically been associated with severe depression, occasionally including suicidal thoughts.

The risk appears greater with higher doses.

Although the precise magnitude of its independent contribution to depression has been debated, the association remains clinically important.

Patients with current or previous major depression generally should not receive reserpine.

Parkinsonism

Dopamine depletion can cause drug-induced parkinsonism.

Manifestations include rigidity, tremor, bradykinesia, and impaired movement.

Symptoms may improve after discontinuation, although recovery can take time.

Gastrointestinal disease

Reserpine can increase gastric secretory activity and has been associated with peptic ulcer complications.

It is generally avoided in patients with active peptic ulcer disease.

Other adverse effects

Chronic treatment may produce fatigue, dizziness, orthostatic hypotension, nasal congestion, sexual dysfunction, edema, and gastrointestinal discomfort.

8. Drug interactions and combination products

Other antihypertensive medications

Concurrent therapy with beta blockers, calcium channel blockers, diuretics, or other antihypertensive agents may increase the risk of hypotension or bradycardia.

Diuretic combinations

Products containing thiazide diuretics may cause hypokalemia, hyponatremia, volume depletion, or metabolic abnormalities.

The clinician should evaluate the entire formulation rather than attributing every finding to reserpine.

Sedatives and alcohol

Alcohol, benzodiazepines, barbiturates, and other CNS depressants may worsen sedation and impair respiratory function.

Digoxin

Concomitant use may increase the clinical significance of bradycardia or conduction disturbances.

Monoamine oxidase inhibitors

Reserpine can interact with monoamine oxidase inhibitors in unpredictable ways.

Current tranylcypromine labeling lists reserpine among contraindicated concomitant medications.

Other monoamine-depleting medications

Tetrabenazine and related VMAT2 inhibitors should not be combined casually with reserpine.

These combinations may increase risks of depression, parkinsonism, hypotension, or other complications.

9. Diagnosis and investigations

Reserpine poisoning is primarily a clinical diagnosis.

Exposure history

Determine whether the patient ingested prescription reserpine, an older combination tablet, or an herbal Rauvolfia preparation.

Establish the time, amount, and possible coingestants.

Physical examination

Assess:

  • Airway and respiratory effort.
  • Level of consciousness.
  • Heart rate and blood pressure.
  • Peripheral perfusion.
  • Body temperature.
  • Neurologic findings.

ECG

Obtain an ECG in significant overdose or when bradycardia, syncope, hypotension, or an uncertain coingestion is present.

Continuous cardiac monitoring is appropriate for symptomatic patients.

Laboratory investigations

For significant poisoning, consider:

  • Bedside glucose.
  • Electrolytes, particularly potassium and sodium.
  • Creatinine and kidney function.
  • Blood gas if respiratory depression or major acid-base disturbance is suspected.
  • Lactate when shock or tissue hypoperfusion is present.

Coingestant testing

After deliberate or uncertain overdose, acetaminophen and salicylate concentrations may be appropriate.

Drug concentrations

Serum reserpine concentrations are not routinely available and have no established role in guiding emergency treatment.

Serum catecholamine measurements are also not useful for routine diagnosis or management.

10. Differential diagnosis

Other medications that may produce bradycardia, hypotension, and altered consciousness include:

  • Beta blockers.
  • Calcium channel blockers.
  • Clonidine.
  • Guanfacine.
  • Sedative-hypnotic medications.
  • Opioids.
  • Digoxin and other cardiac glycosides.
  • Certain antidepressants and antipsychotics.

Clonidine poisoning

Clonidine may resemble reserpine poisoning because it produces sedation, bradycardia, hypotension, and sometimes miosis.

The mechanism differs, however: clonidine primarily stimulates central alpha-2 adrenergic receptors, whereas reserpine depletes monoamine stores.

Other diagnoses

Hypoglycemia, hypothermia, intracranial disease, infection, and metabolic disorders should be considered when the exposure history is uncertain.

11. Treatment

Initial priorities

There is no specific antidote.

Treatment involves maintaining airway protection, adequate ventilation, and organ perfusion until the toxic effects resolve.

Airway and breathing

Provide supplemental oxygen when indicated.

Patients with significant respiratory depression, coma, or loss of airway reflexes may require assisted ventilation or endotracheal intubation.

Hypotension

Assess for dehydration, concurrent diuretics, and other causes of shock.

Appropriately titrated isotonic crystalloid is reasonable when volume depletion is suspected.

Avoid excessive fluids in patients with cardiac dysfunction or other risks of fluid overload.

Vasopressors

If hypotension persists despite appropriate fluid management, norepinephrine is a reasonable preferred vasopressor.

It directly stimulates adrenergic receptors and does not depend primarily on release of stored norepinephrine from sympathetic neurons.

Phenylephrine may be useful in selected situations.

Dopamine is less attractive as a default agent because its effects partly depend on endogenous catecholamine availability and it can increase dysrhythmia risk.

Symptomatic bradycardia

Atropine may be administered according to current resuscitation guidance.

The response may be incomplete.

Persistent hemodynamically important bradycardia may require epinephrine infusion or temporary cardiac pacing after appropriate evaluation.

Cardiac pacing is not automatically indicated for every patient with reserpine-induced bradycardia.

Transient hypertension

Hypertension is uncommon in isolated reserpine poisoning.

It should not be treated unless sufficiently severe to warrant intervention.

If hypertensive emergency develops, use a titratable medication chosen according to the clinical circumstances.

Avoid long-acting antihypertensive treatment that could worsen later hypotension.

Hypothermia

Provide passive or active rewarming according to severity.

Seizures

Seizures are not a common defining feature of reserpine poisoning.

If they occur, investigate alternative causes and coingestants.

Benzodiazepines are appropriate initial treatment for toxin-associated seizures.

12. Gastrointestinal decontamination

Induced vomiting

Do not induce vomiting.

Ipecac is obsolete and may increase aspiration risk.

Gastric lavage

Routine gastric lavage is not recommended.

The benefit of recovering reserpine tablets is uncertain, and the procedure carries significant risks in patients who may rapidly become sedated.

Activated charcoal

A single dose may be considered after a substantial recent ingestion when the airway is protected.

However, the evidence for clinical benefit specifically in reserpine poisoning is limited.

Charcoal is not routinely necessary after a minor exposure.

Enhanced elimination

There is no established role for:

  • Multiple-dose activated charcoal.
  • Forced diuresis.
  • Urinary acidification or alkalinization.
  • Hemodialysis.
  • Hemoperfusion.

Dialysis may still be necessary for conventional medical indications unrelated to enhanced reserpine elimination.

13. Monitoring and disposition

Minor exposure

An asymptomatic patient following a clearly minor exposure may be assessed through a poison center.

The appropriate disposition depends on the formulation, quantity, age, and reliability of the exposure history.

Significant ingestion

Substantial ingestion or an uncertain high-risk exposure requires emergency evaluation.

Observe for sedation, respiratory depression, hypotension, bradycardia, and hypothermia.

Observation duration

The older recommendation of 24 hours remains a reasonable initial approach for potentially significant reserpine ingestion, but it is not a validated universal discharge threshold.

Some patients may require shorter observation after a confidently low-risk exposure.

Others may need longer monitoring because neurologic or cardiovascular effects persist.

Hospital admission

Admission is appropriate for significant sedation, hypotension, bradycardia, hypothermia, respiratory compromise, or important combination-product toxicity.

Intensive care

ICU treatment may be required for coma, respiratory failure, severe hypotension, or shock requiring vasopressors.

Discharge

Discharge requires a return to baseline consciousness, adequate spontaneous ventilation, stable blood pressure and heart rate without ongoing support, and sufficient observation to make subsequent deterioration unlikely.

Patients with intentional ingestion require an appropriate mental health assessment.

14. Pregnancy and lactation

Pregnancy

The former FDA Pregnancy Category C classification is obsolete.

Reserpine crosses the placenta.

Maternal exposure near delivery has historically been associated with neonatal nasal congestion, respiratory difficulty, lethargy, and feeding problems.

Modern obstetric hypertension management generally favors medications with better-established pregnancy safety and efficacy.

Reserpine is not a preferred treatment for hypertension during pregnancy.

Lactation

Reserpine has been reported in human breast milk.

Its potential effects on infant monoamine signaling, blood pressure, feeding, and alertness warrant caution.

Safer antihypertensive alternatives are generally preferred during breastfeeding, particularly when the infant is newborn or medically vulnerable.

The risks of concentrated Rauvolfia herbal preparations during pregnancy or breastfeeding are even less predictable because alkaloid content varies.

15. Expected course and prognosis

Most mild exposures resolve with supportive care.

Clinical findings commonly begin during the first several hours after ingestion.

Sedation and other acute effects often improve within 24–48 hours, but significant poisoning may produce a longer course.

Severe cases can cause respiratory failure, shock, or complications related to prolonged impaired consciousness.

Depression and drug-induced parkinsonism associated with sustained reserpine treatment may take longer to resolve after discontinuation.

The prognosis is generally favorable when significant respiratory and hemodynamic complications are recognized and treated promptly.

16. Clinical pitfalls

Assuming reserpine is a routine modern antihypertensive. Its use is now uncommon, and historical dosing should not be used as contemporary prescribing guidance.

Missing Rauvolfia herbal products. Snake-root preparations can contain clinically important amounts of reserpine and other alkaloids.

Overlooking combination products. Diuretics and other antihypertensives can contribute to hypotension and electrolyte abnormalities.

Assuming the initial clinical examination predicts the entire course. Sedation and cardiovascular effects may evolve.

Expecting a predictable hypertensive phase. Transient hypertension has been reported, but it is unusual.

Using dopamine as the automatic first vasopressor. Direct-acting adrenergic agents, particularly norepinephrine, are generally more rational.

Automatically pacing every bradycardic patient. Intervention should reflect symptoms and perfusion.

Ignoring the risk of depression. A detailed psychiatric history and appropriate follow-up are important during therapeutic exposure.

Inducing vomiting or performing routine lavage. These historical recommendations should be removed.

Assuming dialysis removes reserpine effectively. Extracorporeal elimination has no established routine role.

Applying a rigid 24-hour rule to every case. Observation should be individualized according to severity and clinical recovery.


Key clinical conclusions

Reserpine is a prolonged-acting monoamine-depleting agent that can cause sedation, bradycardia, hypotension, hypothermia, and, in severe cases, coma or circulatory collapse.

Its toxic effects reflect inhibition of VMAT-dependent neurotransmitter storage and may persist after plasma drug concentrations decline.

Treatment is supportive. Atropine may help symptomatic bradycardia, while norepinephrine is a reasonable preferred vasopressor for persistent hypotension.

There is no specific antidote, and neither routine gastric lavage nor extracorporeal removal is established as beneficial.

The most important long-term treatment concerns are psychiatric depression, parkinsonism, and the potential toxicity of other ingredients in historical combination products.


Image description
0 Comments